Key result
Routine discontinuation of antiplatelet drugs in the perioperative period should be discouraged, and risk stratification must be employed to balance hemorrhagic and thrombotic risks.
Why the study?
Does the continuation of antiplatelet therapy compared to routine discontinuation affect hemorrhagic and thrombotic risks in patients scheduled for surgery?
Population
Patients receiving antiplatelet therapy who are scheduled for surgery, particularly urological procedures…
Comparison
Continuation of antiplatelet therapy in the… vs Routine discontinuation of antiplatelet therapy…
Design
Review
Authors
Loading...
Supports cautious antiplatelet continuation with risk stratification; leaves open confirmation by randomized perioperative trials.
Does the continuation of antiplatelet therapy compared to routine discontinuation affect hemorrhagic and thrombotic risks in patients scheduled for surgery?
Routine discontinuation of antiplatelet therapy before surgery should be avoided, and decisions should be individualized based on the patient's specific thrombotic and bleeding risks, in accordance with ACCP guidelines.
Vasudeva et al. (2009) conducted a review in Patients on antiplatelet therapy undergoing urological or non-cardiac surgery. Perioperative continuation vs discontinuation of antiplatelet drugs was evaluated. Routine discontinuation of antiplatelet drugs in the perioperative period should be discouraged, and risk stratification must be employed to balance hemorrhagic and thrombotic risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: